Patients with atopic dermatitis (AD) treated with dupilumab may face a slightly elevated risk of developing psoriasis, with new study data showing a cumulative 3-year incidence of 2.86% compared ...

Dupilumab also had more wins vs. losses for percent-predicted post-bronchodilator FEV 1 worsening of at least 100 mL at week 52 compared with placebo (12.1% vs. 8.2%), according to the analysis.

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children ...

Part B was a 36-week extended active treatment period in which eligible dupilumab recipients from part A maintained their weight-tiered higher- or lower-dose regimen, whereas those in the placebo ...

Dupilumab is undergoing Priority Review by the FDA as an add-on maintenance therapy for adults with uncontrolled COPD and type 2 inflammation, with a target action date of June 27, 2024, according ...

Dupilumab is a human monoclonal antibody that blocks the receptor shared by interleukin-4 (IL-4) and IL-13, both of which are key to the development of type 2 inflammation in chronic obstructive ...

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional ...

The prebronchodilator FEV 1 increased from baseline to week 12 with dupilumab (least-squares mean change, 139 ml [95% CI, 105 to 173]) as compared with placebo (least-squares mean change, 57 ml ...

Between dupilumab and benralizumab, researchers found a significantly reduced rate of asthma exacerbations in the dupilumab group (1.07 per year vs. 1.47 per year; rate ratio, 0.73; 95% CI, 0.63-0 ...

“Dupilumab has the potential to impact the vicious cycle of exacerbations and lung function decline in patients with COPD with type 2 inflammation and high exacerbation risk, who are already on ...